[1] Parker AL,Kavallaris M,McCarroll JA.Microtubules and their role in cellular stress in cancer［J］.Front Oncol,2014,4:153.
[2] Prosser SL,Pelletier L.Mitotic spindle assembly in animal cells: a fine balancing act［J］.Nat Rev Mol Cell Biol,2017,18(3):187-201.
[3] Jordan MA,Wilson L.Microtubules as a target for anticancer drugs［J］.Nat Rev Cancer,2004,4(4):253-265.
[4] Li W,Zhang H,Assaraf YG,et al.Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies［J］.Drug Resist Updat,2016,27:14-29.
[5] Krishna R,Mayer LD.Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs［J］.Eur J Pharm Sci,2000,11(4):265-283.
[6] Hao XY,Widersten M,Ridderstrom M,et al.Co-variation of glutathione transferase expression and cytostatic drug resistance in HeLa cells: establishment of class Mu glutathione transferase M3-3 as the dominating isoenzyme［J］.Biochem J,1994,297 (Pt 1):59-67.
[7] Ogiso Y,Tomida A,Tsuruo T.Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase Ⅱ-directed drugs［J］.Cancer Res,2002,62(17):5008-5012.
[8] Fernald K,Kurokawa M.Evading apoptosis in cancer［J］.Trends Cell Biol,2013,23(12):620-633.
[9] Krauze A,Grinberga S,Krasnova L,et al.Thieno[2,3-b]pyridines——a new class of multidrug resistance (MDR) modulators［J］.Bioorg Med Chem,2014,22(21):5860-5870.
[10] Dostal V,Libusova L.Microtubule drugs: action, selectivity, and resistance across the kingdoms of life［J］.Protoplasma,2014,251(5):991-1005.
[11] Hu T,Li Z,Gao CY,et al.Mechanisms of drug resistance in colon cancer and its therapeutic strategies［J］.World J Gastroenterol,2016,22(30):6876-6889.
[12] Kavallaris M.Microtubules and resistance to tubulin-binding agents［J］.Nat Rev Cancer,2010,10(3):194-204.
[13] Kavallaris M,Annereau JP,Barret JM.Potential mechanisms of resistance to microtubule inhibitors［J］.Semin Oncol,2008,35(3 Suppl 3):S22-S27.
[14] Gan PP,Pasquier E,Kavallaris M.Class Ⅲ beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer［J］.Cancer Res,2007,67(19):9356-9363.
[15] Amos LA.What tubulin drugs tell us about microtubule structure and dynamics［J］.Semin Cell Dev Biol,2011,22(9):916-926.
[16] Löwe J,Li H,Downing KH,et al.Refined structure of αβ-tubulin at 3.5 Å resolution［J］.J Mol Biol,2001,313(5):1045-1057.
[17] Devambatla RK,Namjoshi OA,Choudhary S,et al.Design, synthesis, and preclinical evaluation of 4-substituted-5-methyl-furo[2,3-d]pyrimidines as microtubule targeting agents that are effective against multidrug resistant cancer cells［J］.J Med Chem,2016,59(12):5752-5765.
[18] Philchenkov AA,Zavelevich MP,Tryndyak VP,et al.Antiproliferative and proapoptotic effects of a pyrrole containing arylthioindole in human Jurkat leukemia cell line and multidrug-resistant Jurkat/A4 cells［J］.Cancer Biol Ther,2015,16(12):1820-1829.
[19] Gan PP,McCarroll JA,Po'uha ST,et al.Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaⅢ-tubulin［J］.Mol Cancer Ther,2010,9(5):1339-1348.
[20] Lu Y,Chen J,Xiao M,et al.An overview of tubulin inhibitors that interact with the colchicine binding site［J］.Pharm Res,2012,29(11):2943-2971.
[21] Chamberlain MC,Grimm S,Phuphanich S,et al.A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC)［J］.J Neurooncol,2014,118(2):335-343.
[22] Kasibhatla S,Baichwal V,Cai SX,et al.MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps［J］.Cancer Res,2007,67(12):5865-5871.
[23] Subbiah IM,Lenihan DJ,Tsimberidou AM.Cardiovascular toxicity profiles of vascular-disrupting agents［J］.Oncologist,2011,16(8):1120-1130.
[24] Mahal K,Resch M,Ficner R,et al.Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels［J］.ChemMedChem,2014,9(4):847-854.
[25] Wang XF,Guan F,Ohkoshi E,et al.Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site［J］.J Med Chem,2014,57(4):1390-1402.
[26] Gangjee A,Zhao Y,Raghavan S,et al.Structure-activity relationship and in vitro and in vivo evaluation of the potent cytotoxic anti-microtubule agent N-(4-methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride and its analogues as antitumor agents［J］.J Med Chem,2013,56(17):6829-6844.
[27] Cao D,Liu Y,Yan W,et al.Design, synthesis, and evaluation of in vitro and in vivo anticancer activity of 4-substituted coumarins: A novel class of potent tubulin polymerization inhibitors［J］.J Med Chem,2016,59(12):5721-5739.
[28] Zhou B,Xing C.Diverse molecular targets for chalcones with varied bioactivities［J］.Med Chem (Los Angeles),2015,5(8):388-404.
[29] Gwaltney SL,Imade HM,Barr KJ,et al.Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents［J］.Bioorg Med Chem Lett,2001,11(7):871-874.
[30] Romagnoli R,Baraldi PG,Brancale A,et al.Convergent synthesis and biological evaluation of 2-amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents［J］.J Med Chem,2011,54(14):5144-5153.
[31] Schobert R,Biersack B,Dietrich A,et al.4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin: A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model［J］.J Med Chem,2010,53(18):6595-6602.
[32] Nathwani SM,Hughes L,Greene LM,et al.Novel cis-restricted beta-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro［J］.Oncol Rep,2013,29(2):585-594.
[33] Cai D,Qiu Z,Yao W,et al.YSL-12,a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo［J］.Cancer Chemother Pharmacol,2016,77(6):1217-1229.
[34] Mahal K,Biersack B,Schruefer S,et al.Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors［J］.Eur J Med Chem,2016,118:9-20.
[35] La Regina G,Bai R,Rensen W,et al.Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability［J］.J Med Chem,2011,54(24):8394-8406.
[36] An B,Zhang S,Yan J,et al.Synthesis, in vitro and in vivo evaluation of new hybrids of millepachine and phenstatin as potent tubulin polymerization inhibitors［J］.Org Biomol Chem,2017,15(4):852-862.
[37] Romagnoli R,Baraldi PG,Salvador MK,et al.Discovery and optimization of a series of 2-aryl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazoles as novel anticancer agents［J］.J Med Chem,2012,55(11):5433-5445.
[38] Hwang DJ,Wang J,Li W,et al.Structural optimization of indole derivatives acting at colchicine binding site as potential anticancer agents［J］.ACS Med Chem Lett,2015,6(9):993-997.
[39] Romagnoli R,Baraldi PG,Salvador MK,et al.Synthesis and biological evaluation of 2-(alkoxycarbonyl)-3-anilinobenzo[b]thiophenes and thieno[2,3-b]pyridines as new potent anticancer agents［J］.J Med Chem,2013,56(6):2606-2618.
[40] Wang X,Wu E,Wu J,et al.An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells［J］.PLoS ONE,2013,8(6):e65686.
[41] Romagnoli R,Baraldi PG,Salvador MK,et al.Synthesis, antimitotic and antivascular activity of 1-(3',4',5'-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles［J］.J Med Chem,2014,57(15):6795-6808.
[42] Zhou B,Yu X,Zhuang C,et al.Unambiguous identification of beta-tubulin as the direct cellular target responsible for the cytotoxicity of chalcone by photoaffinity labeling［J］.Chem Med Chem,2016,11(13):1436-1445.
[43] Yang Z,Wu W,Wang J,et al.Synthesis and biological evaluation of novel millepachine derivatives as a new class of tubulin polymerization inhibitors［J］.J Med Chem,2014,57(19):7977-7989.
[44] Wang G,Li C,He L,et al.Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents［J］.Bioorg Med Chem,2014,22(7):2060-2079.
[45] Zhu C,Zuo Y,Wang R,et al.Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence［J］.J Med Chem,2014,57(15):6364-6382.
[46] Yan J,Chen J,Zhang S,et al.Synthesis, evaluation, and mechanism study of novel indole-chalcone derivatives exerting effective antitumor activity through microtubule destabilization in vitro and in vivo［J］.J Med Chem,2016,59(11):5264-5283.
[47] Aoyama A,Katayama R,Oh-Hara T,et al.Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance［J］.Mol Cancer Ther,2014,13(12):2978-2990.
[48] Eurtivong C,Semenov V,Semenova M,et al.3-Amino-thieno[2,3-b]pyridines as microtubule-destabilising agents: Molecular modelling and biological evaluation in the sea urchin embryo and human cancer cells［J］.Bioorg Med Chem,2017,25(2):658-664.
[49] Zheng YB,Gong JH,Liu XJ,et al.A Novel nitrobenzoate microtubule inhibitor that overcomes multidrug resistance exhibits antitumor activity［J］.Sci Rep,2016,6:31472.
[50] Nakagawa-Goto K,Oda A,Hamel E,et al.Development of a novel class of tubulin inhibitor from desmosdumotin B with a hydroxylated bicyclic B-ring［J］.J Med Chem,2015,58(5):2378-2389.
[51] Lee WH,Liu HE,Chang JY,et al.MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2/M arrest in nonresistant and paclitaxel-resistant cancer cells［J］.Pharmacology,2013,92(1-2):90-98.